Aurobindo Pharma shares plunge over 6% after USFDA warning letter for subsidiary

AuroLife Pharma, a wholly-owned step-down subsidiary of the company, has received a warning letter from the United States Food and Drug Administration (USFDA) for its oral solid manufacturing facility situated at Dayton, New Jersey, Aurobindo Pharma said in a BSE filing.

 
– Stocks-Markets-Economic Times

• Share on Facebook
• Tweet it
• Pin it
• Share it
• Email